Using natural products to promote caspase-8-dependent cancer cell death

Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy

(2015) Xiaoyun Dai et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP

(2015) Yuichi Tsuchiya et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The diverse role of RIP kinases in necroptosis and inflammation

(2015) John Silke et al.   NATURE IMMUNOLOGY

Therapeutic applications of TRAIL receptor agonists in cancer and beyond

(2015) Gustavo P. Amarante-Mendes et al.   PHARMACOLOGY & THERAPEUTICS

Necroptosis: Pathway diversity and characteristics

(2015) M. Cristina de Almagro et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation

(2015) C J Henrich et al.   Cell Death & Disease

Distinct roles of RIP1–RIP3 hetero- and RIP3–RIP3 homo-interaction in mediating necroptosis

(2014) X-N Wu et al.   CELL DEATH AND DIFFERENTIATION

RIP kinases: key decision makers in cell death and innate immunity

(2014) F Humphries et al.   CELL DEATH AND DIFFERENTIATION

Combinatorial Immunotherapy of Polyinosinic–Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors

(2014) Toshihiro Nagato et al.   CLINICAL CANCER RESEARCH

Programmed necrosis and necroptosis signalling

(2014) Maria Feoktistova et al.   FEBS Journal

Necroptosis in health and diseases

(2014) Wen Zhou et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Therapeutic exploitation of necroptosis for cancer therapy

(2014) Simone Fulda   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Targeting death receptors for TRAIL by agents designed by Mother Nature

(2014) Sahdeo Prasad et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family

(2013) K Azijli et al.   CELL DEATH AND DIFFERENTIATION

Distinguishing between apoptosis, necrosis, necroptosis and other cell death modalities

(2013) Seamus J. Martin et al.   METHODS

Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2-Induced Apoptosis

(2013) J. S. Swers et al.   MOLECULAR CANCER THERAPEUTICS

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation

(2012) Weiyang He et al.   Autophagy

Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase

(2012) Liming Sun et al.   CELL

The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis

(2012) Jixi Li et al.   CELL

dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8

(2012) Y Estornes et al.   CELL DEATH AND DIFFERENTIATION

Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?

(2012) L.H.A.M. de Wilt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

(2012) L Y Dimberg et al.   ONCOGENE

Combined modality therapy with TRAIL or agonistic death receptor antibodies

(2011) Hope M. Amm et al.   CANCER BIOLOGY & THERAPY

Targeting the extrinsic apoptosis signaling pathway for cancer therapy

(2011) Thomas J. Sayers   CANCER IMMUNOLOGY IMMUNOTHERAPY

Distinct TRAIL Resistance Mechanisms Can Be Overcome by Proteasome Inhibition but not Generally by Synergizing Agents

(2011) C. Menke et al.   CANCER RESEARCH

cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms

(2011) Maria Feoktistova et al.   MOLECULAR CELL

The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs

(2011) Tencho Tenev et al.   MOLECULAR CELL

Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors

(2010) Sujin Lee et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

New insights into apoptosis signaling by Apo2L/TRAIL

(2010) F Gonzalvez et al.   ONCOGENE

Modulation of Apoptosis by Natural Products for Cancer Therapy

(2010) Simone Fulda   PLANTA MEDICA

Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer

(2009) Bodvaël Pennarun et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells

(2009) A Weber et al.   CELL DEATH AND DIFFERENTIATION

Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP

(2009) Tae-Jin Lee et al.   FREE RADICAL BIOLOGY AND MEDICINE

XIAP discriminates between type I and type II FAS-induced apoptosis

(2009) Philipp J. Jost et al.   NATURE

Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer

(2009) B. Jasani et al.   VACCINE

A cell-based high-throughput screen to identify synergistic TRAIL sensitizers

(2008) Nancy Lynn Booth et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

(2008) Devalingam Mahalingam et al.   CANCER TREATMENT REVIEWS

To kill a tumor cell: the potential of proapoptotic receptor agonists

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL INVESTIGATION

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE